Compare Amphastar Pharmaceuticals Inc (AMPH) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Verisign, Inc. trades at $270.69 (market cap $24.58B). The key difference: Verisign, Inc. is far larger — about 29.8× Amphastar Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.2% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | VRSN | |
|---|---|---|
Market Cap | $826.08M | $24.58B |
Sector | Health | Technology |
52-Week High | $30.81 | $310.00 |
52-Week Low | $16.87 | $211.49 |
Enterprise Value | $1.22B | $25.82B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VeriSign (VRSN) trades at $270.11, up 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.67. The company reported Q1 2026 EPS of $2.34, beating expectations, and maintains strong profitability with a net income margin near 50%. Recent news highlights AI-driven domain registration growth and the upcoming Q2 2026 earnings report on July 23, 2026.
The outlook for VRSN is positive, supported by stable revenue growth, high margins, and analyst optimism, but risks include AI disruption to its domain business, contract renewals, and a high debt load. The stock offers potential upside to the consensus target, though investors should monitor earnings execution and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
